Positron Corporation Expands Market Presence with Sale of NeuSight PET-CT Scanner
Positron Corporation (OTC: POSC) has announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist. The NeuSight PET-CT scanner features a 72 cm gantry and high-sensitivity acquisition technology that reduces radiation exposure. The system, which has the smallest footprint in its class, is designed for both cardiology and oncology applications, offering anatomic and functional imaging capabilities.
The scanner supports various studies, including cardiac, tumor, and neurological imaging. According to President Adel Abdullah, this sale to a key opinion leader (KOL) of a larger medical group represents a potential gateway to broader organizational opportunities as Positron expands into the western U.S. market.
Positron Corporation (OTC: POSC) ha annunciato la vendita del suo scanner NeuSight PET-CT a 64 slice a un rinomato cardiologo nucleare. Lo scanner NeuSight PET-CT è dotato di un gantry da 72 cm e di una tecnologia di acquisizione ad alta sensibilità che riduce l'esposizione alle radiazioni. Il sistema, che ha l'ingombro più piccolo della sua categoria, è progettato per applicazioni sia cardiologiche che oncologiche, offrendo capacità di imaging anatomico e funzionale.
Lo scanner supporta diversi tipi di studi, tra cui imaging cardiaco, tumorale e neurologico. Secondo il Presidente Adel Abdullah, questa vendita a un opinion leader (KOL) di un importante gruppo medico rappresenta una potenziale porta d'accesso a opportunità organizzative più ampie, mentre Positron si espande nel mercato dell'ovest degli Stati Uniti.
Positron Corporation (OTC: POSC) ha anunciado la venta de su escáner NeuSight PET-CT de 64 cortes a un destacado cardiólogo nuclear. El escáner NeuSight PET-CT cuenta con un gantry de 72 cm y tecnología de adquisición de alta sensibilidad que reduce la exposición a la radiación. El sistema, que tiene la huella más pequeña en su categoría, está diseñado para aplicaciones tanto en cardiología como en oncología, ofreciendo capacidades de imagen anatómica y funcional.
El escáner admite diversos estudios, incluyendo imágenes cardíacas, tumorales y neurológicas. Según el presidente Adel Abdullah, esta venta a un líder de opinión clave (KOL) de un grupo médico importante representa una posible puerta de entrada a oportunidades organizacionales más amplias a medida que Positron se expande en el mercado del oeste de Estados Unidos.
포지트론 코퍼레이션(OTC: POSC)은 저명한 핵심 심장 전문의에게 NeuSight PET-CT 64슬라이스 스캐너를 판매했다고 발표했습니다. NeuSight PET-CT 스캐너는 72cm 게인트리와 방사선 노출을 줄이는 고감도 획득 기술을 갖추고 있습니다. 이 시스템은 동급 최저의 공간 차지를 자랑하며 심장학과 종양학 모두에 적합하도록 설계되어 해부학적 및 기능적 영상 촬영이 가능합니다.
이 스캐너는 심장, 종양, 신경학적 영상 등 다양한 연구를 지원합니다. 사장 아델 압둘라에 따르면, 이 주요 의료 그룹의 핵심 의견 리더(KOL)에게 판매된 이번 계약은 포지트론이 미국 서부 시장으로 확장하는 데 있어 더 넓은 조직적 기회의 관문이 될 수 있다고 합니다.
Positron Corporation (OTC : POSC) a annoncé la vente de son scanner NeuSight PET-CT 64 coupes à un cardiologue nucléaire de renom. Le scanner NeuSight PET-CT est équipé d’un gantry de 72 cm et d’une technologie d’acquisition à haute sensibilité qui réduit l’exposition aux radiations. Le système, qui possède la plus petite empreinte de sa catégorie, est conçu pour des applications en cardiologie et en oncologie, offrant des capacités d’imagerie anatomique et fonctionnelle.
Le scanner prend en charge diverses études, notamment en imagerie cardiaque, tumorale et neurologique. Selon le président Adel Abdullah, cette vente à un leader d'opinion clé (KOL) d’un grand groupe médical représente une porte d’entrée potentielle vers des opportunités organisationnelles plus larges, alors que Positron s’étend sur le marché de l’ouest des États-Unis.
Positron Corporation (OTC: POSC) hat den Verkauf seines NeuSight PET-CT 64-Schicht-Scanners an einen renommierten Nuklearkardiologen bekannt gegeben. Der NeuSight PET-CT Scanner verfügt über einen 72 cm Gantry und eine hochsensitive Aufnahmetechnologie, die die Strahlenbelastung reduziert. Das System, das die kleinste Stellfläche seiner Klasse aufweist, ist für Anwendungen in Kardiologie und Onkologie konzipiert und bietet anatomische sowie funktionelle Bildgebungsfähigkeiten.
Der Scanner unterstützt verschiedene Untersuchungen, darunter kardiale, tumorbedingte und neurologische Bildgebung. Laut Präsident Adel Abdullah stellt dieser Verkauf an einen wichtigen Meinungsführer (KOL) einer größeren medizinischen Gruppe ein potenzielles Tor zu umfangreicheren organisatorischen Möglichkeiten dar, während Positron in den westlichen US-Markt expandiert.
- Sale of advanced NeuSight PET-CT scanner to a prominent nuclear cardiologist
- Expansion into western U.S. market
- Potential for broader sales opportunities within the larger medical group
- System's versatility supports both cardiology and oncology applications
- None.
Niagara Falls, NY, May 29, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging systems and services, is pleased to announce the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care.
This latest sale highlights the growing demand for Positron’s PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide.
The NeuSight PET-CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter.
Designed for versatility and viability, the NeuSight PET-CT delivers high-performance imaging for both cardiology and oncology applications. Its advanced data acquisition enables faster, more accurate scans, improving diagnostic confidence. Offering both anatomic and functional imaging, it supports a wide range of studies—including cardiac, tumor, and neurological imaging — making it a powerful tool for practices committed to delivering superior patient care.
Adel Abdullah, President of Positron stated, “We are pleased to partner with such a respected physician who is a KOL of a larger, established medical group. This sale reflects the growing recognition of our advanced PET imaging systems and full-service support. We believe this is the beginning of a broader opportunity to serve the entire organization. As we expand into the western U.S., Positron is uniquely positioned to meet new demands and drive the adoption of cardiac PET through unmatched value, reliability, and clinical impact.”
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Some of the risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; and new product introductions by our competitors. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
FAQ
What is the significance of Positron's (POSC) latest NeuSight PET-CT scanner sale?
What are the key features of Positron's (POSC) NeuSight PET-CT scanner?
How does the NeuSight PET-CT scanner benefit medical practices?
What are the applications of Positron's (POSC) NeuSight PET-CT scanner?
